Cutler Group LP Aeterna Zentaris Inc. Call Options Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Oct 26, 2021	SELL	$0.59 - $0.88 $2,891 - $4,312	-4,900 Reduced 64.47%	2,700 $0
Q2 2021 Jul 19, 2021	SELL	$0.83 - $1.14 $63,578 - $87,323	-76,600 Reduced 90.97%	7,600 $0
Q1 2021 Apr 26, 2021	BUY	$0.51 - $3.34 $42,738 - $279,892	83,800 Added 20950.0%	84,200 $9,000
Q1 2019 May 10, 2019	SELL	$3.03 - $4.65 $9,999 - $15,345	-3,300 Reduced 89.19%	400 $0
Q4 2018 Feb 05, 2019	BUY	$1.3 - $3.87 $4,810 - $14,319	3,700 New	3,700 $2,000
Q3 2018 Nov 07, 2018	SELL	$1.6 - $2.03 $4,000 - $5,074	-2,500 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$1.46 - $2.41 $3,066 - $5,061	2,100 Added 525.0%	2,500 $0
Q4 2017 Jan 17, 2018	SELL	$1.87 - $2.7 $3,553 - $5,130	-1,900 Reduced 82.61%	400 $0
Q3 2017 Oct 17, 2017	BUY	$1.81 - $2.23 $4,163 - $5,129	2,300	2,300 $0

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.